Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 11/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 11/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 11/20 | 0.64 |
| ▸ | RELA | Q04206 | 11/20 | 0.64 |
| ▸ | FOS | P01100 | 7/20 | 0.45 |
| ▸ | XPO1 | O14980 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 2/20 | 0.33 |
| ▸ | CASP7 | P55210 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8399259 | 0.62 | LMNA (0.41) | ALDH1A1LMNA | |
| SCHEMBL24943815 | 0.61 | LMNA (0.40) | LMNA | |
| SCHEMBL28113423 | 0.58 | JUN (0.37) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL19146111 | 0.57 | HPGD (0.53) | CYP1A2CASP1CASP7ALDH1A1HSD17B10 | |
| SCHEMBL25652309 | 0.56 | LMNA (0.44) | ALDH1A1HSD17B10LMNA | |
| SCHEMBL27916636 | 0.56 | JUN (0.36) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL15994288 | 0.55 | LMNA (0.33) | XPO1LMNA | |
| SCHEMBL23020769 | 0.55 | LMNA (0.41) | ALDH1A1LMNA | |
| SCHEMBL7422516 | 0.54 | POLB (0.33) | CYP1A2HSD17B10LMNA | |
| SCHEMBL27935360 | 0.54 | PTGS1 (0.36) | JUNNFKB1NFKB2RELAFOS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415765-A1 | PYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | claimed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | claimed |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| EP-2415765-A1 | PYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | JUN 242/4885NFKB1 2708/4885NFKB2 2655/4885 |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | JUN 324/4885NFKB1 2619/4885NFKB2 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.